Diffusion Imaging in Acute Auto-immune Encephalitis

Auto-immune Encephalitis Clinical Trial

Official title:

Diffusion Imaging in Acute Auto-immune Encephalitis : a Cohort of 80 Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04339205
• Other study ID #: Imaging study
• Status: Recruiting
• Start date: February 1, 2020
• Est. completion date: July 1, 2020

Study information

• Verified date: June 2020
• Source: Hospices Civils de Lyon
• Contact: François cotton, phd
• Phone: 04 78 56 91 00
• Email: francois.cotton[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this non randomised retrospective study is to investigate the imaging (MRI) of auto-immune encephalitis at presentation, especially in diffusion-weighted sequences.

Indeed, few series describe the MRI aspect of auto-immune at their beginning. Recognize early MRI abnormalities seen in auto-immune encephalitis could help reduce the time to positive diagnosis and improve the therapeutic management.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: July 1, 2020
• Est. primary completion date: March 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Auto-immune encephalitis proved by biological results (blood and/or CSF sample)

Exclusion Criteria:

• No MRI available

Related Conditions & MeSH terms

• Auto-immune Encephalitis
• Encephalitis
• Hashimoto Disease

Intervention

Other:
• Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available.
The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed. At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium. The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain. We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not.

Locations

Country	Name	City	State
France	Hospices Civils de Lyon	Pierre-Bénite

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MRI characterization, especially in Diffusion-weighted magnetic resonance imaging (DWI-MRI), of auto-immune encephalitis at presentation.	The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed.; At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium.; The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain.; We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not.	at following-up until 24 months